Rafael Holdings, Inc. RFL
1.12 USD +0.08 (+7.69%)
Nov 9, 2026, 11:15 AM EST
1.01 Day range 1.12
0.99 52-week range 3.96
- YTD
- -5.08%
- 1 year
- -13.18%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL). Such investors are advised…
globenewswire.com Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference NEWARK, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation…
benzinga.com Rafael Holdings Q4 EPS $(0.18) Up From $(0.28) YoY, Sales $244.000K Down From $350.000K YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.18) per share. This is a 35.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported…
benzinga.com Rafael Holdings Files New Drug Application To FDA For Approval Of Remibetadex To Treat Neurovisceral Manifestations Of Niemann-Pick Disease Type C Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking…
benzinga.com Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
benzinga.com Why Is Rafael Stock Falling Wednesday? Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of…
benzinga.com Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The…
benzinga.com Rafael Holdings Announced Topline Efficacy And Safety Data From Its Cyclo Therapeutics Subsidiary’s Phase 3 TransportNPC Study Evaluating Trappsol Cyclo In 94 Patients Diagnosed With Niemann-Pick Disease Type C; Trappsol Cyclo Did Not Achieve Statistical Significance Trappsol® Cyclo™ was well tolerated and demonstrated a directionally favorable treatment effect on the primary endpoint, although the result did not achieve statistical significance. Notably, a…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Rafael Holdings Q3 EPS $(0.08) Up From $(0.19) YoY, Sales $179.000K Down From $362.000K YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.08) per share. This is a 57.89 percent increase over losses of $(0.19) per share from the same period last year. The company reported…
benzinga.com Rafael Holdings Announces Last Patient Completed Final 96-Week Study Visit In Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C; Topline Results Expected In H2 Of Calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026The company has received acknowledgement from the FDA that our US Expanded Access…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Rafael Holdings' Cyclo Therapeutics Enters Into Exclusive Licensing Agreement With MIT For Small Molecules To Improve Myelination In Apoe4 Positive Alzheimer's Disease Rafael Holdings, Inc. (NYSE:RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology ("MIT") covering…
benzinga.com Rafael Holdings Q2 EPS $(0.13) Up From $(0.19) YoY, Sales $211.000K Up From $77.000K YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.13) per share. This is a 31.58 percent increase over losses of $(0.19) per share from the same period last year. The company reported…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Rafael Holdings Q3 EPS $(0.19) Up From $(1.36) YoY, Sales $362.00K Up From $336.00K YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.19) per share. This is a 86.03 percent increase over losses of $(1.36) per share from the same period last year. The company reported…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Rafael Holdings Updates Terms Of Rights Offering, Granting 1 Non-Transferable Subscription Right Per Share Or Equivalent Public Warrant Held As Of May 9, 2025, Allowing Holders To Purchase 0.603 Shares Of Class B Common Stock At $1.28 Per Share, With Public Warrant Holders Receiving 0.3525 Rights Per Warrant And Full Rights Granted Per 3 Warrants Held Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today provided an update to the subscription rights related to its Public Warrants in connection with its previously announced rights offering.Under the…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Rafael Holdings Revises Subscription Rights Following Prior $25M Rights Offering To Support Development And Potential Launch Of Trappsol Cyclo Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced revised subscription rights in connection with its previously announced rights offering.Holders of record as of May 9, 2025 (the "Record…
- benzinga.com Rafael Holdings Announces Proposed Terms Of $25M Rights Offering To Support Its Commitment To Development And Potential Launch Of Trappsol Cyclo. Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our…
- benzinga.com Rafael Holdings Q4 EPS $(0.19) Down From $0.06 YoY, Sales $165.00K Up From $68.00K YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.19) per share. This is a 416.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported…
benzinga.com Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - benzinga.com Rafael And Cyclo Therapeutics Have Agreed To Combine To Focus Trappsol Cyclo For Niemann-pick Disease Type C1 On consummation of the merger, Rafael will issue Class B shares to Cyclo Therapeutics' shareholders, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings…
- benzinga.com Rafael Holdings Q4 EPS $0.06 Up From $(0.24) YoY, Sales $68.00K Down From $69.00K YoY Rafael Holdings (NYSE:RFL) reported quarterly earnings of $0.06 per share. This is a 125 percent increase over losses of $(0.24) per share from the same period last year. The company reported $68.00…
- benzinga.com Cyclo Therapeutics Ended The Quarter With ~$0.8M Of Cash. Subsequent To Quarter-End, The Company Generated Gross Proceeds Of $5M From The Sale Of Securities In Private Placements Of The Co's Securities Continued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end
- benzinga.com Rafael Holdings Q3 EPS $(0.06) Up From $(0.28) YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.06) per share. This is a 78.57 percent increase over losses of $(0.28) per share from the same period last year.
- benzinga.com Rafael Holdings Announces Up To $5M Share Repurchase Program Rafael Holdings, Inc. (NYSE:RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. "We remain committed to
- benzinga.com Rafael Holdings Q2 EPS $(0.14) Down From $(0.12) YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.14) per share. This is a 16.67 percent decrease over losses of $(0.12) per share from the same period last year.
- benzinga.com Top Real Estate Stocks That May Plunge The most overbought stocks in the real estate sector presents an opportunity to go short on these overvalued companies.
- benzinga.com Rafael Holdings Q1 EPS $(0.22) Up From $(0.75) YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.22) per share. This is a 70.67 percent increase over losses of $(0.75) per share from the same period last year.
- benzinga.com Rafael Holdings To Focus On Strategic Business Development Initiatives And Curtail Early Stage Development Activities; As Of July 31, 2022, The Company Held Cash, Cash Equivalents And Marketable Securities Of $63.2M Rafael Holdings, Inc. (NYSE:RFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute in order to reduce spending and…
- benzinga.com Rafael Holdings Q4 EPS $(0.24) Up From $(0.75) YoY Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.24) per share. This is a 68 percent increase over losses of $(0.75) per share from the same period last year.
- benzinga.com Cornerstone Pharmaceuticals Announces Successful Completion Of Phase 1b Clinical Trial For CPI-613 In Combination With Gemcitabine And Cisplatin In Patients With Biliary Tract Cancer Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful
- benzinga.com Alibaba, Zoom Video And 76 Biggest Movers From Yesterday Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
- benzinga.com Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said its treatment for Idiopathic Pulmonary Fibrosis was well tolerated in a Phase 2a study.